Olmesartan French Delisting Delayed, But Still Big Hit For Daiichi Sankyo
Executive Summary
The antihypertensive olmesartan is to lose its reimbursement status in France next year, on the grounds that its efficacy had been shown to be less convincing that that of other angiotensin receptor blockers.